Compare National Beverage Corp. (FIZZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs TG Therapeutics Inc — how do they compare? National Beverage Corp. trades at $30.32 (market cap $2.89B), while TG Therapeutics Inc trades at $54.91 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.8× National Beverage Corp.'s market cap, and TG Therapeutics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and TG Therapeutics Inc for 15 Days on average.
| FIZZ | TGTX | |
|---|---|---|
Market Cap | $2.89B | $8.16B |
Volume | 553,950 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $59.06 |
52-Week Low | $29.20 | $26.94 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $2.84B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.58, up 3.31% today, but faces bearish technical signals with recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margins improved to 15.55% in 2025. The company maintains strong profitability with 40.13% ROE but faces margin pressure from input costs. A $3.25 special dividend payment in July 2026 reduced shareholder equity significantly.
Outlook remains challenging with analyst consensus leaning bearish (50% sell ratings). While valuation appears reasonable (P/E 16.58), stagnant growth and consecutive earnings misses pose headwinds. The key opportunity lies in potential revenue recovery, but investors face risks from competitive pressures and ongoing margin compression.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
